General Information of Drug Combination (ID: DC1EEK3)

Drug Combination Name
Ethinyl Estradiol Imatinib
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Ethinyl Estradiol   DMODJ40 Imatinib   DM7RJXL
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 5.73
Bliss Independence Score: 5.73
Loewe Additivity Score: 6.74
LHighest Single Agent (HSA) Score: 6.74

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ethinyl Estradiol
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [2]
Female hypogonadism GA30.6 Approved [3]
Hot flushes GA30 Approved [2]
Obsolete atrophic vulva N.A. Approved [2]
Ethinyl Estradiol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Agonist [15]
------------------------------------------------------------------------------------
Ethinyl Estradiol Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [16]
------------------------------------------------------------------------------------
Ethinyl Estradiol Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [17]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [18]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Metabolism [19]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [20]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [19]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [21]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Ethinyl Estradiol Interacts with 196 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Hydroxylation [19]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [16]
Gamma-aminobutyric acid receptor subunit pi (GABRP) OTGKA8WS GBRP_HUMAN Decreases Expression [12]
Ectoderm-neural cortex protein 1 (ENC1) OTJEUB6U ENC1_HUMAN Decreases Expression [12]
Na(+)/H(+) exchange regulatory cofactor NHE-RF1 (NHERF1) OTFK8KDP NHRF1_HUMAN Increases Expression [12]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Increases Expression [12]
Band 4.1-like protein 2 (EPB41L2) OT6UABPM E41L2_HUMAN Increases Expression [12]
Tetraspanin-1 (TSPAN1) OTZQPIYK TSN1_HUMAN Decreases Expression [12]
Microfibrillar-associated protein 3-like (MFAP3L) OTNMHSAH MFA3L_HUMAN Increases Expression [12]
Gamma-butyrobetaine dioxygenase (BBOX1) OTKEX4RK BODG_HUMAN Decreases Expression [12]
Nebulette (NEBL) OT2WH1NC NEBL_HUMAN Decreases Expression [12]
ATP-dependent DNA helicase Q5 (RECQL5) OTVZMP1Q RECQ5_HUMAN Decreases Expression [12]
Sorbin and SH3 domain-containing protein 2 (SORBS2) OTJSX44Y SRBS2_HUMAN Decreases Expression [12]
Serine protease 23 (PRSS23) OT6DQAM1 PRS23_HUMAN Decreases Expression [12]
NADH dehydrogenase 1 beta subcomplex subunit 6 (NDUFB6) OTIXNT91 NDUB6_HUMAN Increases Expression [12]
Secretoglobin family 1D member 2 (SCGB1D2) OTSYWZAQ SG1D2_HUMAN Increases Expression [12]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [12]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Increases Expression [12]
Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA) OTWJTCRK PCCA_HUMAN Increases Expression [12]
Alkaline phosphatase, placental type (ALPP) OTZU4G9W PPB1_HUMAN Increases Expression [12]
Collagen alpha-2(V) chain (COL5A2) OT5VOSQE CO5A2_HUMAN Decreases Expression [12]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [12]
Interleukin-6 receptor subunit alpha (IL6R) OTCQL07Z IL6RA_HUMAN Increases Expression [12]
Matrilysin (MMP7) OTVT3SEJ MMP7_HUMAN Increases Expression [12]
Stromelysin-2 (MMP10) OTJDWW8Q MMP10_HUMAN Decreases Expression [12]
Retinol-binding protein 1 (RBP1) OTRP1MFC RET1_HUMAN Decreases Expression [12]
Tropomyosin alpha-1 chain (TPM1) OTD73X6R TPM1_HUMAN Decreases Expression [12]
Interferon alpha-inducible protein 6 (IFI6) OTWOOAM4 IFI6_HUMAN Decreases Expression [12]
Alkaline phosphatase, germ cell type (ALPG) OTCIM29R PPBN_HUMAN Increases Expression [12]
Creatine kinase B-type (CKB) OTUCKOTT KCRB_HUMAN Increases Expression [12]
Collagen alpha-1(V) chain (COL5A1) OT24078H CO5A1_HUMAN Increases Expression [12]
Galanin peptides (GAL) OTB3VPTO GALA_HUMAN Increases Expression [12]
cAMP-dependent protein kinase catalytic subunit beta (PRKACB) OT6RMDCE KAPCB_HUMAN Affects Expression [12]
Insulin-like growth factor-binding protein 5 (IGFBP5) OTRE5V0C IBP5_HUMAN Decreases Expression [12]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Decreases Expression [12]
Transcription factor HIVEP2 (HIVEP2) OTVOMCW4 ZEP2_HUMAN Decreases Expression [12]
Collagen alpha-1(XV) chain (COL15A1) OTTFKK18 COFA1_HUMAN Increases Expression [12]
Replication factor C subunit 3 (RFC3) OT1MS7AO RFC3_HUMAN Increases Expression [12]
Exosome RNA helicase MTR4 (MTREX) OTSQY30V MTREX_HUMAN Increases Expression [12]
G protein-activated inward rectifier potassium channel 1 (KCNJ3) OTHQG16J KCNJ3_HUMAN Decreases Expression [12]
Retinol-binding protein 2 (RBP2) OTR8QG5V RET2_HUMAN Decreases Expression [12]
ADP-ribosylation factor 3 (ARF3) OTYYQX85 ARF3_HUMAN Decreases Expression [12]
Transforming growth factor beta-2 proprotein (TGFB2) OTC0TXEP TGFB2_HUMAN Decreases Expression [12]
Phosphoserine phosphatase (PSPH) OTV1PVAX SERB_HUMAN Decreases Expression [12]
Protein jagged-1 (JAG1) OT3LGT6K JAG1_HUMAN Decreases Expression [12]
4-aminobutyrate aminotransferase, mitochondrial (ABAT) OTXAGR7J GABT_HUMAN Decreases Expression [12]
Low-density lipoprotein receptor-related protein 2 (LRP2) OTZ6W681 LRP2_HUMAN Decreases Expression [12]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Increases Expression [12]
Cyclic AMP-responsive element-binding protein 5 (CREB5) OTJDUJPI CREB5_HUMAN Increases Expression [12]
Transcription factor SOX-4 (SOX4) OTSS40SS SOX4_HUMAN Decreases Expression [12]
Amino acid transporter heavy chain SLC3A1 (SLC3A1) OT56V01A SLC31_HUMAN Decreases Expression [12]
Cadherin-18 (CDH18) OTC06P9H CAD18_HUMAN Decreases Expression [12]
Calcyphosin (CAPS) OTC9GZ2M CAYP1_HUMAN Increases Expression [12]
Transcription factor Dp-2 (TFDP2) OTKQFX5H TFDP2_HUMAN Decreases Expression [12]
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (PDE3A) OTKUW1WT PDE3A_HUMAN Decreases Expression [12]
Next to BRCA1 gene 1 protein (NBR1) OTVRL7J9 NBR1_HUMAN Decreases Expression [12]
Pericentriolar material 1 protein (PCM1) OTFM133C PCM1_HUMAN Decreases Expression [12]
Neutral amino acid transporter B(0) (SLC1A5) OTE2H26Q AAAT_HUMAN Increases Expression [12]
Dual specificity protein phosphatase 5 (DUSP5) OTH96RA7 DUS5_HUMAN Increases Expression [12]
Protein Dok-7 (DOK7) OTR2V7HO DOK7_HUMAN Increases Expression [12]
Protein GREB1 (GREB1) OTU6ZA26 GREB1_HUMAN Increases Expression [12]
Piercer of microtubule wall 1 protein (PIERCE1) OTONT0CN PIRC1_HUMAN Decreases Expression [12]
Retrotransposon Gag-like protein 5 (RTL5) OT9ZJR3N RTL5_HUMAN Decreases Expression [12]
Protein phosphatase 1J (PPM1J) OTM6GDJJ PPM1J_HUMAN Increases Expression [12]
Immediate early response gene 5-like protein (IER5L) OT6IG629 IER5L_HUMAN Increases Expression [12]
Disabled homolog 2-interacting protein (DAB2IP) OTF456VC DAB2P_HUMAN Affects Expression [12]
Anoctamin-1 (ANO1) OTSREUNI ANO1_HUMAN Increases Expression [12]
Proline-rich membrane anchor 1 (PRIMA1) OT9ITT3P PRIMA_HUMAN Decreases Expression [12]
E3 ubiquitin-protein ligase TRIM22 (TRIM22) OTJBLG5R TRI22_HUMAN Decreases Expression [12]
Solute carrier family 25 member 45 (SLC25A45) OTP7EAUM S2545_HUMAN Decreases Expression [12]
PACRG-like protein (PACRGL) OT5DEP0X PACRL_HUMAN Increases Expression [12]
N-acetylaspartate synthetase (NAT8L) OTA96AVN NAT8L_HUMAN Decreases Expression [12]
Retinoic acid-induced protein 3 (GPRC5A) OTPOCWR7 RAI3_HUMAN Decreases Expression [12]
Two pore channel protein 2 (TPCN2) OTLAF3ED TPC2_HUMAN Decreases Expression [12]
LIM domain only protein 3 (LMO3) OTR7AJHN LMO3_HUMAN Decreases Expression [12]
DEP domain-containing mTOR-interacting protein (DEPTOR) OTCBP1BT DPTOR_HUMAN Increases Expression [12]
Epidermal growth factor receptor kinase substrate 8-like protein 1 (EPS8L1) OT83O8WI ES8L1_HUMAN Decreases Expression [12]
Complexin-3 (CPLX3) OT0YTMN2 CPLX3_HUMAN Decreases Expression [12]
Protein kinase C-binding protein NELL1 (NELL1) OTF3TX3N NELL1_HUMAN Decreases Expression [12]
LIM/homeobox protein Lhx4 (LHX4) OTVX3J6S LHX4_HUMAN Increases Expression [12]
E3 ubiquitin-protein ligase MIB2 (MIB2) OTJCC3HS MIB2_HUMAN Decreases Expression [12]
Dedicator of cytokinesis protein 10 (DOCK10) OTI3MBLV DOC10_HUMAN Decreases Expression [12]
Endoplasmic reticulum resident protein 27 (ERP27) OTVMGE2H ERP27_HUMAN Decreases Expression [12]
Hedgehog-interacting protein (HHIP) OT77RQYS HHIP_HUMAN Decreases Expression [12]
TSC22 domain family protein 3 (TSC22D3) OT03UM03 T22D3_HUMAN Decreases Expression [12]
Neurturin (NRTN) OT4PAKUY NRTN_HUMAN Increases Expression [12]
Ras-like protein family member 11B (RASL11B) OTHEVZS6 RSLBB_HUMAN Decreases Expression [12]
Mitochondrial ribosome-associated GTPase 1 (MTG1) OTC9U1LI MTG1_HUMAN Decreases Expression [12]
Melanophilin (MLPH) OT7ADCXL MELPH_HUMAN Increases Expression [12]
RNA-binding protein 24 (RBM24) OTQI1AR1 RBM24_HUMAN Increases Expression [12]
Keratin-associated protein 2-1 (KRTAP2-1) OTV1SGF2 KRA21_HUMAN Decreases Expression [12]
Keratin, type I cytoskeletal 23 (KRT23) OTQW6UAG K1C23_HUMAN Decreases Expression [12]
Cysteine-rich secretory protein LCCL domain-containing 1 (CRISPLD1) OT38HXJP CRLD1_HUMAN Increases Expression [12]
Aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) OTAQD3YV ARNT2_HUMAN Decreases Expression [12]
Plexin-A4 (PLXNA4) OT5XKB3Q PLXA4_HUMAN Decreases Expression [12]
Transcription and mRNA export factor ENY2 (ENY2) OTTNU8RK ENY2_HUMAN Decreases Expression [12]
Signal peptide, CUB and EGF-like domain-containing protein 2 (SCUBE2) OT661S7D SCUB2_HUMAN Decreases Expression [12]
Cytochrome P450 26B1 (CYP26B1) OT92XA92 CP26B_HUMAN Decreases Expression [12]
Olfactomedin-like protein 3 (OLFML3) OTDN45FN OLFL3_HUMAN Increases Expression [12]
Cytokine-inducible SH2-containing protein (CISH) OT8T5NYL CISH_HUMAN Increases Expression [12]
ATPase family AAA domain-containing protein 3A (ATAD3A) OTWF6HBP ATD3A_HUMAN Decreases Expression [12]
Kv channel-interacting protein 1 (KCNIP1) OTGLGK1R KCIP1_HUMAN Decreases Expression [12]
Denticleless protein homolog (DTL) OTC29RYE DTL_HUMAN Increases Expression [12]
Peroxisomal sarcosine oxidase (PIPOX) OTWTCOTN SOX_HUMAN Increases Expression [12]
A disintegrin and metalloproteinase with thrombospondin motifs 9 (ADAMTS9) OTV3Q0DS ATS9_HUMAN Increases Expression [12]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A) OTHCDQ22 PRGC1_HUMAN Decreases Expression [12]
Protein NDRG2 (NDRG2) OT5L6KD7 NDRG2_HUMAN Decreases Expression [12]
Rho family-interacting cell polarization regulator 2 (RIPOR2) OTXB6LIR RIPR2_HUMAN Decreases Expression [12]
Transcription factor HES-2 (HES2) OTMWY2KV HES2_HUMAN Increases Expression [12]
Tolloid-like protein 2 (TLL2) OTHZ4TBL TLL2_HUMAN Increases Expression [12]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) OTX8L3M5 SAHH2_HUMAN Affects Expression [13]
Putative hydrolase DDAH2 (DDAH2) OT8Q40G2 DDAH2_HUMAN Affects Expression [13]
Small integral membrane protein 6 (SMIM6) OTRGL3O1 SMIM6_HUMAN Affects Expression [13]
G0/G1 switch protein 2 (G0S2) OT8FL49L G0S2_HUMAN Affects Expression [13]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Affects Expression [13]
Homeobox protein MOX-1 (MEOX1) OTJEMT2D MEOX1_HUMAN Affects Expression [13]
Diacylglycerol kinase epsilon (DGKE) OTWS86AS DGKE_HUMAN Affects Expression [13]
Phospholipid-transporting ATPase ID (ATP8B2) OTH5WJ09 AT8B2_HUMAN Affects Expression [13]
Programmed cell death protein 4 (PDCD4) OTZ6NXUX PDCD4_HUMAN Affects Expression [13]
Sclerostin domain-containing protein 1 (SOSTDC1) OTAKDNSM SOSD1_HUMAN Affects Expression [13]
Transmembrane protein 64 (TMEM64) OTO9IDFD TMM64_HUMAN Affects Expression [13]
Echinoderm microtubule-associated protein-like 6 (EML6) OTE1MUQS EMAL6_HUMAN Affects Expression [13]
PX domain-containing protein kinase-like protein (PXK) OTSP1WLK PXK_HUMAN Affects Expression [13]
Protein limb expression 1 homolog (LIX1) OT1CPNCC LIX1_HUMAN Affects Expression [13]
Uncharacterized protein FAM241A (FAM241A) OTC12ETA F241A_HUMAN Affects Expression [13]
Syntaxin-binding protein 6 (STXBP6) OTUEKTIP STXB6_HUMAN Affects Expression [13]
POC1 centriolar protein homolog B (POC1B) OTDIMIRZ POC1B_HUMAN Affects Expression [13]
Solute carrier family 2, facilitated glucose transporter member 12 (SLC2A12) OT0EDNV9 GTR12_HUMAN Affects Expression [13]
Pleckstrin homology-like domain family A member 1 (PHLDA1) OTFTWMIQ PHLA1_HUMAN Affects Expression [13]
Peroxidasin homolog (PXDN) OTFGGM9R PXDN_HUMAN Affects Expression [13]
Secreted frizzled-related protein 3 (FRZB) OTTO3DPY SFRP3_HUMAN Affects Expression [13]
DNA endonuclease RBBP8 (RBBP8) OTRHJ3GI CTIP_HUMAN Affects Expression [13]
Transmembrane protease serine 4 (TMPRSS4) OTCCGY2K TMPS4_HUMAN Affects Expression [13]
Cdc42 effector protein 3 (CDC42EP3) OTUZ3U9Z BORG2_HUMAN Affects Expression [13]
Teneurin-1 (TENM1) OTSKSU4V TEN1_HUMAN Affects Expression [13]
RNA polymerase II elongation factor ELL2 (ELL2) OTZJRTFM ELL2_HUMAN Affects Expression [14]
Mothers against decapentaplegic homolog 6 (SMAD6) OTUZZWUD SMAD6_HUMAN Affects Expression [14]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [22]
RAS guanyl-releasing protein 1 (RASGRP1) OTX9WN2E GRP1_HUMAN Affects Expression [14]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Expression [23]
Cytochrome c oxidase subunit 3 (COX3) OTNNGBYJ COX3_HUMAN Increases Expression [24]
Prothrombin (F2) OTNFSM49 THRB_HUMAN Increases Expression [25]
Renin (REN) OT52GZR2 RENI_HUMAN Increases Activity [26]
ATP synthase subunit a (ATP6) OTPHOGLX ATP6_HUMAN Increases Expression [24]
Antithrombin-III (SERPINC1) OTDFATG0 ANT3_HUMAN Decreases Activity [27]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Decreases Expression [28]
Lutropin subunit beta (LHB) OT5GBOVJ LSHB_HUMAN Decreases Activity [29]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Increases Expression [30]
Histidine-rich glycoprotein (HRG) OTPLUFOG HRG_HUMAN Decreases Expression [31]
Sex hormone-binding globulin (SHBG) OTPWU5IW SHBG_HUMAN Increases Expression [32]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Affects Expression [33]
Vitamin K-dependent protein S (PROS1) OTXQWNOI PROS_HUMAN Decreases Expression [27]
Chromogranin-A (CHGA) OTXYX5JH CMGA_HUMAN Affects Expression [14]
Keratin, type II cytoskeletal 5 (KRT5) OTVGI9HT K2C5_HUMAN Affects Expression [14]
Beta-1,4-galactosyltransferase 1 (B4GALT1) OTBCXEK7 B4GT1_HUMAN Increases Expression [34]
Myelin and lymphocyte protein (MAL) OTBM30SW MAL_HUMAN Affects Expression [14]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [35]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Activity [36]
Insulin-like growth factor-binding protein complex acid labile subunit (IGFALS) OTTWCZYM ALS_HUMAN Decreases Expression [28]
ETS translocation variant 5 (ETV5) OTE2OBM4 ETV5_HUMAN Affects Expression [14]
Radiation-inducible immediate-early gene IEX-1 (IER3) OTZJI5FZ IEX1_HUMAN Affects Expression [14]
Solute carrier organic anion transporter family member 1A2 (SLCO1A2) OTO70C5O SO1A2_HUMAN Decreases Expression [23]
Cysteine--tRNA ligase, cytoplasmic (CARS1) OTOUZF6O SYCC_HUMAN Affects Expression [14]
Serine--tRNA ligase, cytoplasmic (SARS1) OTFKXQ1O SYSC_HUMAN Affects Expression [14]
CCAAT/enhancer-binding protein delta (CEBPD) OTNBIPMY CEBPD_HUMAN Affects Expression [14]
Inhibin beta E chain (INHBE) OTOI2NYG INHBE_HUMAN Affects Expression [14]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) OTOWDUNT PTEN_HUMAN Affects Expression [14]
Transformer-2 protein homolog beta (TRA2B) OTZYQW52 TRA2B_HUMAN Increases Expression [37]
Small ribosomal subunit protein RACK1 (RACK1) OTZBCQ1U RACK1_HUMAN Increases Expression [38]
Schlafen family member 5 (SLFN5) OTT1AESL SLFN5_HUMAN Affects Expression [14]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) OTXEE550 APR_HUMAN Affects Expression [14]
Four and a half LIM domains protein 2 (FHL2) OT0OAYWT FHL2_HUMAN Affects Expression [14]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Activity [39]
Erythroferrone (ERFE) OTSES1HA ERFE_HUMAN Affects Expression [14]
FYVE, RhoGEF and PH domain-containing protein 3 (FGD3) OTIH6283 FGD3_HUMAN Affects Expression [14]
Na(+)/H(+) exchange regulatory cofactor NHE-RF3 (PDZK1) OTGFK4MH NHRF3_HUMAN Increases Expression [34]
Early estrogen-induced gene 1 protein (EEIG1) OT2BMEAE EEIG1_HUMAN Increases Expression [34]
Very-long-chain (HACD2) OTAZO9F6 HACD2_HUMAN Affects Expression [14]
Retrotransposon-derived protein PEG10 (PEG10) OTWD2278 PEG10_HUMAN Affects Expression [14]
Ly6/PLAUR domain-containing protein 1 (LYPD1) OT0HSGML LYPD1_HUMAN Affects Expression [14]
Stonin-2 (STON2) OT01JHHE STON2_HUMAN Affects Expression [14]
Protein NDRG1 (NDRG1) OTVO66BO NDRG1_HUMAN Affects Expression [14]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Affects Expression [14]
Mediator of RNA polymerase II transcription subunit 8 (MED8) OTSIZ1I7 MED8_HUMAN Affects Expression [14]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Expression [23]
Tribbles homolog 3 (TRIB3) OTG5OS7X TRIB3_HUMAN Affects Expression [14]
Protein associated with UVRAG as autophagy enhancer (RUBCNL) OTMQIDOI PACER_HUMAN Affects Expression [14]
Tetratricopeptide repeat protein 12 (TTC12) OTDB24YV TTC12_HUMAN Affects Expression [14]
Matrix-remodeling-associated protein 5 (MXRA5) OTXZBWCU MXRA5_HUMAN Affects Expression [14]
Signal-induced proliferation-associated 1-like protein 2 (SIPA1L2) OT8NJE5D SI1L2_HUMAN Affects Expression [14]
Kelch-like protein 14 (KLHL14) OTYOS55H KLH14_HUMAN Affects Expression [14]
Transcription factor MafF (MAFF) OT9B7MX0 MAFF_HUMAN Affects Expression [14]
Proton-coupled zinc antiporter SLC30A1 (SLC30A1) OTY8J0S4 ZNT1_HUMAN Affects Expression [14]
SET-binding protein (SETBP1) OTKGCOSR SETBP_HUMAN Affects Expression [14]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Uptake [40]
Cytochrome P450 (CYP2B) OTDDG81I Q14097_HUMAN Increases ADR [41]
------------------------------------------------------------------------------------
⏷ Show the Full List of 196 DOT(s)
Indication(s) of Imatinib
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [4]
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive N.A. Approved [5]
Choroidal neovascularization 9B76 Approved [5]
Chronic eosinophilic leukemia N.A. Approved [5]
Chronic myelogenous leukaemia 2A20.0 Approved [6]
Chronic myeloid leukaemia 2A20 Approved [7]
Dermatofibrosarcoma protuberans N.A. Approved [5]
Gastrointestinal stromal tumour 2B5B Approved [5]
Leukemia N.A. Approved [5]
Malignant peripheral nerve sheath tumor N.A. Approved [5]
Myeloproliferative neoplasm 2A20 Approved [5]
Pulmonary hypertension BB01 Approved [5]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [8]
Intestinal cancer 2C0Z Phase 3 [6]
Lung cancer 2C25.0 Phase 2 [6]
Idiopathic hypereosinophilic syndrome N.A. Investigative [5]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [9]
Scleroderma 4A42 Investigative [5]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [9]
Systemic mastocytosis 2A21.0 Investigative [10]
Imatinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mcl-1 messenger RNA (MCL-1 mRNA) TTN6ORK MCL1_HUMAN . [10]
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [45]
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Inhibitor [45]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Inhibitor [45]
HUMAN fusion protein Bcr-Abl (Bcr-Abl) TTE63HY BCR_HUMAN/ABL1_HUMAN Inhibitor [9]
------------------------------------------------------------------------------------
Imatinib Interacts with 6 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [46]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [47]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [48]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [49]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [50]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [48]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DTP(s)
Imatinib Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [51]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [52]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [53]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [54]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [55]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [56]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [57]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Metabolism [53]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Imatinib Interacts with 48 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Expression [58]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [58]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Decreases Expression [59]
Eukaryotic translation initiation factor 4E (EIF4E) OTDAWNLA IF4E_HUMAN Decreases Expression [59]
Fructose-bisphosphate aldolase C (ALDOC) OTEC13I5 ALDOC_HUMAN Decreases Expression [59]
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHB) OT2NHE5E ODPB_HUMAN Decreases Expression [59]
Eukaryotic translation initiation factor 4B (EIF4B) OTE8TXA8 IF4B_HUMAN Decreases Expression [59]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) OT5BZ1J9 P85A_HUMAN Decreases Expression [59]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [59]
Hexokinase-4 (GCK) OTR3Q0NN HXK4_HUMAN Decreases Expression [59]
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA) OT83PT85 PP2AA_HUMAN Increases Expression [59]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [60]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [61]
Autophagy-related protein 13 (ATG13) OTYMHNEJ ATG13_HUMAN Increases Phosphorylation [42]
Keratin, type I cytoskeletal 14 (KRT14) OTUVZ1DW K1C14_HUMAN Increases Expression [62]
Heat shock protein beta-1 (HSPB1) OTHFZ8ED HSPB1_HUMAN Increases Expression [61]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Phosphorylation [63]
ATP-dependent 6-phosphofructokinase, muscle type (PFKM) OT1QY9JM PFKAM_HUMAN Decreases Expression [64]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [65]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [61]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Decreases Expression [66]
Keratin, type II cytoskeletal 5 (KRT5) OTVGI9HT K2C5_HUMAN Increases Expression [62]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [67]
Transcription factor EB (TFEB) OTJUJJQY TFEB_HUMAN Affects Localization [42]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [61]
Interleukin-4 receptor subunit alpha (IL4R) OTTXOTCW IL4RA_HUMAN Increases Expression [61]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [63]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [63]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Expression [68]
Crk-like protein (CRKL) OTOYSD1R CRKL_HUMAN Decreases Phosphorylation [69]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [42]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Expression [61]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [68]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [70]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Increases Expression [71]
NGFI-A-binding protein 2 (NAB2) OTG4BDF3 NAB2_HUMAN Increases Expression [61]
TRAF family member-associated NF-kappa-B activator (TANK) OTZSGFIK TANK_HUMAN Increases Expression [61]
NACHT, LRR and PYD domains-containing protein 3 (NLRP3) OTZM6MHU NLRP3_HUMAN Increases Expression [72]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Increases Activity [71]
Docking protein 1 (DOK1) OTGVRLW6 DOK1_HUMAN Decreases Phosphorylation [73]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Increases Expression [42]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [74]
V-type proton ATPase subunit H (ATP6V1H) OTX17GQ9 VATH_HUMAN Increases Expression [42]
LYR motif-containing protein 9 (LYRM9) OT1MILTK LYRM9_HUMAN Affects Response To Substance [75]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Response To Substance [76]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Response To Substance [77]
Tyrosine-protein kinase Lyn (LYN) OTP686K2 LYN_HUMAN Decreases Response To Substance [69]
Serine/threonine-protein kinase PLK1 (PLK1) OTRZX45T PLK1_HUMAN Increases Response To Substance [65]
------------------------------------------------------------------------------------
⏷ Show the Full List of 48 DOT(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Ethinyl estradiol FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7071).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Imatinib FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
7 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 078340.
8 ClinicalTrials.gov (NCT04356495) Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). U.S. National Institutes of Health.
9 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
10 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
11 Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos. 2007 Dec;35(12):2270-80.
12 The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
13 Dose- and time-dependent transcriptional response of Ishikawa cells exposed to genistein. Toxicol Sci. 2016 May;151(1):71-87.
14 The genomic response of Ishikawa cells to bisphenol A exposure is dose- and time-dependent. Toxicology. 2010 Apr 11;270(2-3):137-49. doi: 10.1016/j.tox.2010.02.008. Epub 2010 Feb 17.
15 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
16 P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
17 Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev. 2004 Oct;36(3-4):497-509.
18 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
19 The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
20 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
21 The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003 Aug;56(2):232-7.
22 Development of a common carp (Cyprinus carpio) pregnane X receptor (cPXR) transactivation reporter assay and its activation by azole fungicides and pharmaceutical chemicals. Toxicol In Vitro. 2017 Jun;41:114-122. doi: 10.1016/j.tiv.2017.02.023. Epub 2017 Mar 1.
23 UDCA and CDCA alleviate 17-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats. Toxicol Appl Pharmacol. 2016 Nov 15;311:12-25. doi: 10.1016/j.taap.2016.10.011. Epub 2016 Oct 12.
24 Enhanced levels of several mitochondrial mRNA transcripts and mitochondrial superoxide production during ethinyl estradiol-induced hepatocarcinogenesis and after estrogen treatment of HepG2 cells. Carcinogenesis. 1998 Dec;19(12):2187-93. doi: 10.1093/carcin/19.12.2187.
25 Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost. 1996 Nov;76(5):729-34.
26 Influence of the M235T polymorphism of human angiotensinogen (AGT) on plasma AGT and renin concentrations after ethinylestradiol administration. J Clin Endocrinol Metab. 2000 Nov;85(11):4331-7. doi: 10.1210/jcem.85.11.6932.
27 Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab. 2007 Jun;92(6):2074-9. doi: 10.1210/jc.2007-0026. Epub 2007 Mar 20.
28 Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab. 2000 May;85(5):1918-22. doi: 10.1210/jcem.85.5.6527.
29 Estrogenic Compounds or Adiponectin Inhibit Cyclic AMP Response to Human Luteinizing Hormone in Mouse Leydig Tumor Cells. Biology (Basel). 2019 Jun 11;8(2):45. doi: 10.3390/biology8020045.
30 Oral ethinyl estradiol, but not transdermal 17beta-estradiol, increases plasma C-reactive protein levels in men. Thromb Haemost. 2000 Aug;84(2):359-60.
31 Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way. Thromb Haemost. 1995 Mar;73(3):484-7.
32 Oral contraceptives moderately effect bone resorption markers and serum-soluble interleukin-6 receptor concentrations. Calcif Tissue Int. 2002 Jan;70(1):11-21. doi: 10.1007/s002230020035. Epub 2001 Dec 21.
33 Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity. Toxicology. 2014 Jun 5;320:46-55. doi: 10.1016/j.tox.2014.03.007. Epub 2014 Mar 28.
34 Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol. 2004 Feb;18(2):402-11. doi: 10.1210/me.2003-0202. Epub 2003 Nov 6.
35 Ethinylestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature. Eur J Endocrinol. 2005 Apr;152(4):597-604. doi: 10.1530/eje.1.01880.
36 Synthetic estrogen-mediated activation of ERK 2 intracellular signaling molecule. Gynecol Endocrinol. 2003 Oct;17(5):423-8. doi: 10.1080/09513590312331290338.
37 Regulation of alternative splicing of liver scavenger receptor class B gene by estrogen and the involved regulatory splicing factors. Endocrinology. 2007 Nov;148(11):5295-304. doi: 10.1210/en.2007-0376. Epub 2007 Aug 2.
38 Effects of endocrine disrupting chemicals on the expression of RACK1 and LPS-induced THP-1 cell activation. Toxicology. 2022 Oct;480:153321. doi: 10.1016/j.tox.2022.153321. Epub 2022 Sep 13.
39 Agonistic effects of diverse xenobiotics on the constitutive androstane receptor as detected in a recombinant yeast-cell assay. Toxicol In Vitro. 2018 Feb;46:335-349. doi: 10.1016/j.tiv.2017.09.014. Epub 2017 Sep 18.
40 Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J Pharmacol Exp Ther. 2004 Apr;309(1):156-64. doi: 10.1124/jpet.103.062091. Epub 2004 Jan 13.
41 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
42 Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
43 Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. doi: 10.1158/1078-0432.CCR-05-1778.
44 Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer. 2004 Sep 1;101(5):979-88. doi: 10.1002/cncr.20457.
45 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
46 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
47 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
48 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
49 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
50 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
51 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
52 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
53 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
54 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
55 Drug Interactions Flockhart Table
56 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
57 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
58 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
59 A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
60 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
61 Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. PLoS One. 2011;6(9):e24831. doi: 10.1371/journal.pone.0024831. Epub 2011 Sep 14.
62 Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatolog Treat. 2004 Jul;15(4):253-5. doi: 10.1080/09546630410015556.
63 Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004 Aug 15;104(4):1094-9. doi: 10.1182/blood-2003-12-4266. Epub 2004 Apr 20.
64 Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact. 2015 May 25;233:147-56. doi: 10.1016/j.cbi.2015.03.028. Epub 2015 Apr 8.
65 Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget. 2015 Aug 21;6(24):20231-40. doi: 10.18632/oncotarget.4047.
66 AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells. Cancer Sci. 2021 Jan;112(1):194-204. doi: 10.1111/cas.14698. Epub 2020 Nov 16.
67 Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 2010 Jan 1;70(1):150-9. doi: 10.1158/0008-5472.CAN-09-1449. Epub 2009 Dec 22.
68 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
69 Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol. 2007 May;78(5):417-31. doi: 10.1111/j.1600-0609.2007.00835.x.
70 The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 2001 Mar;59(3):453-61. doi: 10.1124/mol.59.3.453.
71 Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
72 Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. Arch Toxicol. 2022 Apr;96(4):1075-1087. doi: 10.1007/s00204-022-03245-x. Epub 2022 Feb 22.
73 Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
74 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
75 Identification of Genes That Modulate Susceptibility to Formaldehyde and Imatinib by Functional Genomic Screening in Human Haploid KBM7 Cells. Toxicol Sci. 2016 May;151(1):10-22. doi: 10.1093/toxsci/kfw032. Epub 2016 Mar 22.
76 Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005 Sep 15;65(18):8224-32. doi: 10.1158/0008-5472.CAN-05-0303.
77 Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009 Jul;45(10):1877-89. doi: 10.1016/j.ejca.2009.04.005. Epub 2009 May 4.